News archive search

Search the Newsreel

Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.

Showing
1–36
Matches
42
Sources here
17
Companies here
1
Search results Stored financial headlines

Active search

42 matching headlines

Ticker or company: IMNNMain company stories
Clear
Latest

Stock Titan Earnings

Armistice Capital (IMNN) discloses 9.99% Imunon stake via Master Fund

Armistice Capital, LLC and Steven Boyd have reported a beneficial ownership of 9.99% of Imunon, Inc.'s common stock, totaling 450,315 shares. This stake is held through Armistice Capital Master Fund Ltd., with Armistice Capital acting as the investment manager and Steven Boyd as its managing member, thereby exercising shared voting and dispositive power. The filing indicates that the …

Main company 🇺🇸 United States
Read at Stock Titan
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Just inNext headlines
nasdaq.com Market update Main company 🇺🇸 United States

Imunon (IMNN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Tuesday, Aug. 11, 2026 at 11 a.m. ET CALL PARTICIPANTS President and Chief Executive Officer - Stacy R. LindborgChief Medical Officer - Douglas V. FallerInterim Chief Financial Officer - Joshua BlacherExecutive Chairman - Michael H. TardugnoManaging Director of …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
seekingalpha.com Earnings Main company 🇺🇸 United States

Imunon outlines OVATION 3 enrollment pace of 0.5 patients per site per month while planning early 2027 OVATION 2 data presentation

Earnings Call Insights: Imunon, Inc. (IMNN) Q2 2026 MANAGEMENT VIEW * “The second quarter marked another period of focused execution and key validation of both IMNN-001, our lead asset, and our TheraPlas platform.” (President, CEO & Director Stacy Lindborg) * “We remain very encouraged …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Search results

Matching headlines

External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.

AlphaStreet Earnings Main company 🇺🇸 United States

Imunon Q2 2026 Loss Shrinks 42.6%: -$0.54/Share vs -$0.94 Expected

Imunon, Inc. reported a Q2 2026 loss of $0.54 per share, significantly beating analyst expectations of $0.94 per share due to strong cost management. This marks a 42.6% improvement against estimates and a substantial reduction from the $2.15 loss in Q2 2025. While the …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
nasdaq.com Regulatory and legal Main company 🇺🇸 United States

IMUNON Advances OVATION 3 Trial Of IMNN-001; Enrollment Expected To Complete In 1H29

(RTTNews) - IMUNON, Inc. (IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, reported its second-quarter 2026 financial results and provided a business update, with investors focusing on continued progress in the pivotal Phase 3 OVATION 3 trial of IMNN-001 in newly diagnosed advanced ovarian …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Earnings call transcript: Imunon beats Q2 2026 EPS forecast as shares stay weak

Imunon (IMNN) reported a smaller-than-expected loss of $0.54 per share in Q2 2026, surpassing analyst estimates of a $0.93 loss. Despite the beat, the stock remained under pressure due to investor concerns about cash needs, its early-stage clinical pipeline, and the long road ahead …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Imunon, Inc. 2Q 2026: Net loss $(2.83M), EPS $(0.54) — 10-Q Summary

Imunon, Inc. reported a net loss of $(2.83M) and an EPS of $(0.54) for the second quarter of 2026. The company ended the quarter with $11.86M in cash and restricted cash but expressed substantial doubt about its ability to continue as a going concern. …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Imunon reports Q2 2026 net loss $2.8M; cash $6.9M, advances Phase 3 OVATION 3

Imunon reported a Q2 2026 net loss of $2.8 million and cash and cash equivalents of $6.9 million as of June 30, 2026. The company is advancing its Phase 3 OVATION 3 study for lead candidate IMNN-001, citing accelerated enrollment and positive clinical signals. …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update

IMUNON, Inc. reported its second-quarter 2026 financial results, highlighting significant progress in the Phase 3 OVATION 3 study for its lead candidate IMNN-001 for ovarian cancer. The company noted rapid enrollment exceeding expectations and new preliminary data from a Phase 2 MRD study showing …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Quiver Quantitative Earnings Main company 🇺🇸 United States

IMUNON reports $2.8 million Q2 loss as OVATION 3 enrollment advances

IMUNON (IMNN) reported a net loss of $2.8 million, or $0.54 per share, for Q2 2026, with operating expenses remaining unchanged from the previous year. The company is advancing its Phase 3 OVATION 3 study for ovarian cancer, with enrollment expected to conclude by …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Nigeria Market update Main company 🇺🇸 United States

Form 8K Imunon Inc For: 11 August By Investing.com

This article reports on the filing of Form 8K by Imunon Inc. on August 11. It briefly mentions that the information is provided by Investing.com. The piece also includes some unrelated popular news headlines and market data.

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Imunon, Inc. (IMNN) general counsel grants and sells 2,541 shares

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, received 2,541 shares of common stock on July 31, 2026, as part of her base salary, valued at $1.59 per share. She subsequently sold all 2,541 shares on August 3, 2026, at a weighted average …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Imunon (NASDAQ: IMNN) awards director 6,180 shares for board fees

Imunon, Inc. (NASDAQ: IMNN) director Donald P. Braun was granted 6,180 shares of common stock on July 31, 2026, valued at $1.59 per share. These shares were issued in lieu of cash for a portion of his board fees. Following this transaction, Braun directly …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Imunon (IMNN) director granted 6,934 shares of stock for board fees

Imunon, Inc. director James E. Dentzer was granted 6,934 shares of common stock on July 31, 2026, as compensation for a portion of his board fees. The stock grant was valued at $1.59 per share, bringing his total direct holdings to 21,897 shares. This …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Yahoo! Finance Canada Earnings Main company 🇺🇸 United States

IMUNON to Hold Second Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, August 11, 2026

IMUNON, Inc. will host a conference call on Tuesday, August 11, 2026, at 11:00 a.m. EDT to discuss its second quarter 2026 financial results. The call will also provide an update on its clinical development program, including progress for IMNN-001 in advanced ovarian cancer. …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Imunon Inc expected to post a loss of 93 cents a share - Earnings Preview

Imunon Inc is anticipated to report a loss of 93 cents per share, according to an earnings preview. This financial outlook provides investors with an expectation for the company's upcoming earnings report. The full article is available through TradingView, which offers access to Reuters …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Moomoo Earnings Main company 🇺🇸 United States

Imunon (IMNN.US) will release its earnings report on August 4.

Imunon (IMNN.US) is scheduled to release its earnings report on August 4. This announcement provides investors with a key date to anticipate financial results from the company.

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Market update Main company 🇺🇸 United States

IMUNON reports faster-than-expected enrollment in ovarian cancer trial

IMUNON Inc. has announced that enrollment for its Phase 3 OVATION 3 trial of IMNN-001 for advanced ovarian cancer is progressing faster than anticipated, with an enrollment rate exceeding projections. The company expects to complete enrollment by the second quarter of 2029 and highlighted …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Earnings Main company 🇺🇸 United States

IMUNON Reports Strong Enrollment Momentum in Phase 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer

IMUNON, Inc. is experiencing rapid and exceeding-expectations enrollment in its pivotal Phase 3 OVATION 3 trial for IMNN-001 in advanced ovarian cancer. This strong momentum is attributed to promising survival data from the Phase 2 OVATION 2 study and a favorable safety profile, with …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Benzinga Earnings Main company 🇺🇸 United States

EXCLUSIVE: Imunon Outlines Accelerated Timeline, Strong Safety Data for Pivotal Ovarian Cancer Study

Imunon Inc. provided an update on its Phase 3 OVATION 3 trial for IMNN-001 in ovarian cancer, reporting significantly accelerated site activation and patient enrollment speeds that exceed industry benchmarks. The company anticipates full enrollment by Q2 2029 and has scheduled interim analyses that …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Imunon Inc (IMNN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Imunon Inc (IMNN), detailing its current stock price momentum, support and resistance levels, and various technical indicator readings. It highlights that IMNN's price momentum score is 5.09, suggesting range-bound swing trading as the stock trades between $1.28 …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Imunon Inc (IMNN) Institutional Confidence

This article from TradingKey provides an overview of Imunon Inc.'s (IMNN) institutional confidence score. It highlights the company's current stock price, market cap, and details key institutional shareholdings and their recent activity. The institutional confidence score remains at 3.00 with no change from the …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Imunon Inc (IMNN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Imunon Inc (IMNN), noting its current valuation score of 6.86, which ranks 274 out of 385 in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio, and states that P/B, P/S, and P/CF relevant …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

Imunon Inc (IMNN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Imunon Inc (IMNN), listing its major shareholders and institutional holdings. It shows that Armistice Capital LLC is the largest individual shareholder, and provides data on institutional ownership trends over several quarters, highlighting changes in shares held and …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Imunon, Inc. Revenue Breakdown – NASDAQ:IMNN

The article "Imunon, Inc. Revenue Breakdown – NASDAQ:IMNN" is a financial overview of Imunon, Inc. (IMNN) on TradingView. It provides access to the company's financials, including statements, statistics, dividends, earnings, and segment performance. The page appears to be a portal for investors to research …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Market update Main company 🇺🇸 United States

IMNN|Imunon Inc|Price:1.510|Chg%:-0.150

Imunon Inc. (IMNN) is a clinical-stage biotechnology company focused on treatments utilizing the body's natural mechanisms, distinct from conventional therapies. The company is developing non-viral DNA technology across two modalities: TheraPlas for solid tumors and PlaCCine for viral antigens. Their lead program, IMNN-001, an …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingKey Earnings Main company 🇺🇸 United States

Imunon Inc (IMNN) Financial Health: Profitability & Balance Sheet Analysis

This article analyzes the financial health of Imunon Inc (IMNN), providing a score of 6.70 which ranks it 222 out of 386 in the Biotechnology & Medical Research industry. It notes the company's robust financial status but low operating efficiency. Key financial metrics such …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Market source Earnings Main company 🇺🇸 United States

Imunon, Inc. (IMNN) stock price, news, quote and history

Imunon, Inc. (IMNN) stock experienced a decline, trading at $1.5000 with a -0.66% change after hours on July 24, 2026. The clinical-stage biotechnology company focuses on developing immunotherapies and vaccines, with lead programs including IMNN-001 for ovarian cancer and IMNN-101 for COVID-19. The article …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GlobeNewswire Market update Main company 🇺🇸 United States

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

IMUNON, Inc. (Nasdaq: IMNN) announced it will present new data on its DNA-based IL-12 immunotherapy, IMNN-001, for advanced ovarian cancer at the inaugural AACR Conference on Drug Discovery and Development. The presentation will highlight findings from the Phase 2 OVATION-2 study, demonstrating IMNN-001's safety, …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Pluang Earnings Main company 🇺🇸 United States

IMUNON presents promising Phase 2 data for IMNN-001 immunotherapy in advanced ovarian cancer at AACR D3 conference.

IMUNON, Inc. presented positive Phase 2 clinical trial data for its DNA-based immunotherapy, IMNN-001, at the AACR D3 conference. The data indicates that IMNN-001 can significantly improve overall survival in patients with advanced ovarian cancer by locally delivering interleukin-12 to tumors, enhancing immune response …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Market update Main company 🇺🇸 United States

Ovarian cancer trial links IMUNON's IMNN-001 to 14.7 more months

IMUNON (Nasdaq: IMNN) announced new translational and clinical data on its DNA-based IL-12 immunotherapy, IMNN-001, for advanced ovarian cancer, to be presented at the AACR D3 conference. The data highlights a numerical median overall survival increase of 14.7 months for IMNN-001 plus chemotherapy compared …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
TradingView Earnings Main company 🇺🇸 United States

Price to earnings forward of Imunon, Inc. – LSE:0HUZ

This article provides financial information for Imunon, Inc. (LSE:0HUZ), specifically focusing on its price-to-earnings forward metric. The content is primarily a data point embedded within a larger financial data platform, TradingView, highlighting the value and change of this financial indicator. The article doesn't offer …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
AllSci Macro sensitivity Main company 🇺🇸 United States

IMUNON's IL-12 Therapy Breaks Ovarian Cancer Safety Barrier

Imunon's IL-12 gene therapy (IMNN-001) has shown promising early safety and efficacy signals in Phase II trials for newly diagnosed advanced ovarian cancer. Preliminary data indicate lower rates of residual disease and higher circulating tumor DNA clearance in patients receiving IMNN-001 compared to control, …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
GuruFocus Market update Main company 🇺🇸 United States

Insider Sell: Susan Eylward Sells 2,150 Shares of Imunon Inc (IMNN)

Susan Eylward, General Counsel and Corporate Secretary at Imunon Inc's subsidiary, sold 2,150 shares of Imunon Inc (IMNN) on July 20, 2026. After this transaction, Eylward now holds 2,896 shares. This sale contributes to a total of three insider sells and no insider buys …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Stock Titan Earnings Main company 🇺🇸 United States

Imunon (IMNN) counsel granted, then sells 2,150 shares of Common Stock

Imunon, Inc.'s General Counsel and Corporate Secretary, Susan Eylward, reported two Common Stock transactions. She first received 2,150 shares at $1.83 each as part of her base salary on July 17, 2026. Three days later, on July 20, 2026, Eylward sold all 2,150 of …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026
Investing.com Earnings Main company 🇺🇸 United States

Imunon general counsel Susan Eylward sells $3,830 in stock

Imunon's general counsel, Susan Eylward, recently sold 2,150 shares worth $3,830 after acquiring the same number of shares as part of her salary compensation. These transactions occurred while the stock trades near its 52-week low, though InvestingPro analysis suggests it is undervalued with high …

IMNN main company
Sharemaestro market context Price below Trend Line 52 weeks -74.6% · Next-week setup negative 41.9% IMNN stored weekly price path from 22 Aug 2025 to 14 Aug 2026

Find financial news

Search the Newsreel

Use one field or combine several. Results are newest first.

Evidence context